Comparative Pharmacology
Head-to-head clinical analysis: AVENTYL HYDROCHLORIDE versus DOXEPIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVENTYL HYDROCHLORIDE versus DOXEPIN HYDROCHLORIDE.
AVENTYL HYDROCHLORIDE vs DOXEPIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline hydrochloride, the active ingredient in Aventyl Hydrochloride, is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. It also has antihistaminic, anticholinergic, and sedative properties.
Doxepin is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, thereby increasing their concentrations in the synaptic cleft. It also exhibits potent histamine H1 receptor antagonism, leading to antihistaminic effects, and has anticholinergic, alpha-adrenergic blocking, and anti-serotonergic properties.
25 mg orally three times daily; may increase gradually to 150 mg/day in divided doses. Maximum dose 150 mg/day.
25-150 mg orally at bedtime; initially 25 mg, may increase gradually to 150 mg. For minor depression: 25-50 mg orally at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 19–24 hours; may be prolonged in elderly and patients with hepatic impairment.
Terminal elimination half-life: 8-24 hours (mean 15 hours). Steady-state achieved in 3-5 days. Active metabolite nordoxepin has half-life of 31-50 hours.
Primarily renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal excretion accounts for ~30%.
Primarily renal (50-60% as metabolites, <5% unchanged). Biliary/fecal: approximately 20-30%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant